

Reference Data

3rd Quarter - Fiscal Year 2021
(April 1, 2021 to December 31, 2021)

Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations
 - Sales by Region p. 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Result of Major Consolidated Subsidiary p. 8
- Prescription Pharmaceutical Operations:
 - New Drug Development-Taisho Pharmaceutical p. 9
- Launch of New Products p.11

Taisho Pharmaceutical Holdings Co.,Ltd.

Consolidated Financial Data

(Millions of yen)

	March 2021(FY2020)**				March 2022(FY2021)**				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Net sales	71,532	138,851	203,287	267,920	63,884	130,161	200,051	269,000	269,000
(YOY%)	-	-	-	-	(-10.7%)	(-6.3%)	(-1.6%)	(+0.4%)	(+0.4%)
Self-Medication operations	54,178	108,910	161,416	217,056	53,623	110,598	169,745	231,100	231,100
Prescription Pharmaceutical operations	17,353	29,940	41,870	50,863	10,260	19,562	30,306	37,900	37,900
Gross profit on sales	44,231	87,286	126,993	163,815	39,739	78,523	122,205	165,200	165,500
Selling, general and administrative expenses	34,842	70,991	106,129	143,849	37,063	76,210	115,071	154,300	151,000
Research and development expenses	4,209	9,429	14,354	20,251	4,629	9,673	14,291	20,600	21,600
(% Sales)	(5.9%)	(6.8%)	(7.1%)	(7.6%)	(7.2%)	(7.4%)	(7.1%)	(7.7%)	(8.0%)
Advertising expenses	6,107	11,905	17,645	25,017	7,029	15,325	24,352	32,100	32,000
Sales promotion expenses	3,561	7,546	11,313	15,255	3,421	6,932	10,656	14,700	13,100
Personnel expenses	8,201	16,522	25,039	32,953	9,701	18,353	26,481	34,600	33,100
Operating Profit	9,389	16,295	20,864	19,965	2,676	2,313	7,133	11,000	14,500
(YOY%)	(+12.8%)	(+12.2%)	(+22.1%)	(-5.5%)	(-71.5%)	(-85.8%)	(-65.8%)	(-44.9%)	(-27.4%)
Earnings before the amortization of goodwill and trademarks	12,399	22,233	29,839	32,008	5,756	8,563	16,455	23,400	26,400
Ordinary Profit	11,117	18,859	24,742	25,946	4,033	4,223	11,493	15,500	18,500
(YOY%)	(+45.3%)	(+29.1%)	(+22.0%)	(+6.0%)	(-63.7%)	(-77.6%)	(-53.5%)	(-40.3%)	(-28.7%)
Profit attributable to owners of parent	6,064	11,294	14,235	13,316	1,179	2,908	8,974	11,500	10,500
(YOY%)	(-44.9%)	(-23.6%)	(-20.0%)	(-34.0%)	(-80.5%)	(-74.3%)	(-37.0%)	(-13.6%)	(-21.1%)
Comprehensive income	3,537	10,802	16,541	28,920	6,953	12,965	12,987	-	-
(YOY%)	(-33.3%)	(+36.4%)	(+88.0%)	(+241.4%)	(+96.6%)	(+20.0%)	(-21.5%)	-	-
Basic EPS (yen)	75.98	141.51	178.35	166.84	14.78	35.95	110.43	141.20	131.45
Diluted EPS (yen)	75.89	141.34	178.12	166.63	14.75	35.90	110.30	141.04	131.29
BPS (yen)	8,862.95	8,949.88	8,967.90	9,129.95	9,131.84	9,085.03	9,025.57	9,072.76	9,158.01
Dividend per share (yen)	-	50.00	-	100.00	-	50.00	-	100.00	100.00
Payout ratio	-	-	-	59.9%	-	-	-	70.8%	76.1%
Capital expenditure	2,659	5,701	8,182	15,121	1,779	7,749	10,553	16,600	17,600
Depreciation and amortization	3,673	7,206	10,925	14,700	3,508	7,347	10,958	14,500	14,000
Total assets	858,187	861,043	861,329	876,923	877,471	885,595	875,757	879,000	879,000
Shareholders' equity	736,944	744,157	745,217	758,406	757,842	763,880	759,789	763,000	761,000
Return on equity (%)*	-	-	-	1.9%	-	-	-	1.6%	1.4%
Return on assets (%)*	-	-	-	1.5%	-	-	-	1.3%	1.2%
Equity ratio (%)	82.4%	83.0%	83.1%	83.1%	83.1%	84.1%	84.5%	84.6%	83.2%
Overseas sales	27,063	47,518	67,833	92,607	24,824	47,729	71,820	101,700	98,400
Overseas sales ratio (% of total sales)	36.1%	32.6%	31.7%	32.8%	38.9%	36.7%	36.4%	37.8%	36.6%
Number of employees	9,356	9,304	9,234	9,195	9,254	9,203	9,165	-	-

* Average of the beginning and year-end balance of shareholders' equity / total assets

**Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

<Reference>

• E=Estimates

• Full year forecasts for the fiscal year ending March 31, 2022 were announced on November 9, 2021.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2020		End of FY2021 3Q*		change	
	(March 31, 21)	% total	(December 31, 21)	% total		
(Assets)						
I Current assets:	357,731	40.8%	365,322	41.7%	+7,591	
Cash and deposits	250,178		249,075		-1,102	
Notes and accounts receivable-trade	51,609		60,858		+9,248	
Marketable securities	4,017		4,000		-16	
Inventories	46,384		42,728		-3,656	
Other	5,540		8,658		+3,117	
II Fixed assets:	519,192	59.2%	510,434	58.3%	-8,757	
(1) Tangible fixed assets:	113,194	(12.9%)	116,081	(13.3%)	+2,886	
Buildings and structures	51,876		49,957		-1,919	
Machinery, equipment and vehicles	14,494		14,613		+118	
Land	37,429		37,455		+25	
Other	9,393		14,054		+4,661	The new Biofermin Pharmaceutical Co., Ltd. factory and others
(2) Intangible fixed assets:	216,532	(24.7%)	214,373	(24.5%)	-2,159	
Goodwill	128,612		126,767		-1,844	
Sales rights	453		388		-65	
Trademarks	69,258		68,515		-742	
Software	10,341		10,436		+94	
Other	7,867		8,265		+398	
(3) Investments and other assets:	189,464	(21.6%)	179,980	(20.6%)	-9,484	
Investment securities	156,055		146,196		-9,858	Impact of the sale of stock and other factors
Shares of subsidiaries and affiliates	12,261		12,539		+277	
Net defined benefit assets	10,620		11,045		+424	
Deferred tax assets	8,892		7,693		-1,198	
Other	1,634		2,505		+870	
Total assets	876,923	100.0%	875,757	100.0%	-1,166	
(Liabilities)						
I Current liabilities:	57,666	6.6%	59,211	6.8%	+1,545	
Notes and accounts payable-trade	14,672		16,338		+1,666	
Accounts payable	16,068		15,653		-415	
Accrued income taxes	3,275		1,904		-1,371	
Refund liability	-		7,263		+7,263	
Provision for bonuses	3,523		4,707		+1,184	
Other	20,126		13,344		-6,782	
II Long-term liabilities:	60,849	6.9%	56,755	6.5%	-4,094	
Net defined benefit liabilities	21,321		21,540		+218	
Deferred taxes liabilities	32,747		28,041		-4,705	
Other	6,780		7,173		+392	
Total liabilities	118,516	13.5%	115,967	13.2%	-2,548	
(Net assets)						
I Shareholders' equity	697,598	79.6%	707,810	80.8%	+10,211	
Common stock	30,000		30,000		-	
Capital surplus	12		-		-12	
Retained earnings	703,036		698,836		-4,200	
Treasury stock	-35,450		-21,025		+14,424	Impact of making Biofermin Pharmaceutical Co., Ltd. a wholly owned subsidiary
II Accumulated other comprehensive income	31,105	3.5%	32,163	3.7%	+1,057	
Valuation difference on securities	30,026		23,588		-6,437	
Foreign currency translation adjustment	-235		7,327		+7,563	
Remeasurements of defined benefit plans	1,315		1,247		-68	
III Share acquisition rights	801	0.1%	753	0.1%	-48	
IV Non-controlling interests	28,900	3.3%	19,062	2.2%	-9,838	Impact of making Biofermin Pharmaceutical Co., Ltd. a wholly owned subsidiary
Total net assets	758,406	86.5%	759,789	86.8%	+1,382	
Total liabilities and net assets	876,923	100.0%	875,757	100.0%	-1,166	

* The accounting standard for revenue recognition has been applied from FY2021 onwards.

Consolidated P/L Statement

(Millions of yen)

	FY2020*		FY2021*		YOY change	
	3Q	% total	3Q	% total		
Net sales	203,287	100.0%	200,051	100.0%	-3,235	
Cost of sales	76,186	37.5%	77,846	38.9%	+1,659	
Gross profit on sales	127,100	62.5%	122,205	61.1%	-4,895	
Provision for sales returns	107		-		-107	
Gross profit	126,993	62.5%	122,205	61.1%	-4,787	
Selling, general and administrative expenses	106,129	52.2%	115,071	57.5%	+8,942	
Research and development expenses	14,354		14,291		-63	
Advertising expenses	17,645		24,352		+6,707	
Sales promotion expenses	11,313		10,656		-656	
Personnel expenses	25,039		26,481		+1,441	
Other	37,775		39,289		+1,513	
Operating Profit	20,864	10.3%	7,133	3.6%	-13,730	
Non-operating income	4,190	2.1%	4,947	2.5%	+757	
Non-operating expenses	311	0.2%	588	0.3%	+276	
Ordinary Profit	24,742	12.2%	11,493	5.7%	-13,249	
Extraordinary income	17	0.0%	4,114	2.1%	+4,097	FY2021: Sale of investment securities +4,069
Extraordinary losses	597	0.3%	95	0.0%	-502	
Profit before income taxes and minority interests	24,162	11.9%	15,513	7.8%	-8,649	
Income taxes	8,261	4.1%	5,070	2.5%	-3,190	
Profit	15,901	7.8%	10,442	5.2%	-5,458	
Profit attributable to non-controlling interests	1,665	0.8%	1,468	0.7%	-197	
Profit attributable to owners of parent	14,235	7.0%	8,974	4.5%	-5,261	

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2021(FY2020)*				March2022(FY2021)*				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Self-Medication operations	54,178	108,910	161,416	217,056	53,623	110,598	169,745	231,100	231,100
(YOY%)	-	-	-	-	(-1.0%)	(+1.5%)	(+5.2%)	(+6.5%)	(+6.5%)
Japan	27,009	60,598	92,383	122,977	28,873	62,832	96,318	129,400	131,300
Overseas	26,692	47,105	67,152	91,697	24,270	46,735	72,339	100,400	98,000
Other	476	1,206	1,881	2,382	479	1,030	1,087	1,300	1,800
Prescription Pharmaceutical operations	17,353	29,940	41,870	50,863	10,260	19,562	30,306	37,900	37,900
(YOY%)	-	-	-	-	(-40.9%)	(-34.7%)	(-27.6%)	(-25.5%)	(-25.5%)
Ethical drugs	16,961	29,388	41,047	49,965	9,480	18,171	28,616	35,900	36,800
Other	392	551	823	898	780	1,391	1,690	2,000	1,100
Total	71,532	138,851	203,287	267,920	63,884	130,161	200,051	269,000	269,000

*Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2021(FY2020)**				March2022(FY2021)**				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Self-Medication operations	5,483	12,526	16,855	19,395	3,112	3,994	8,889	16,000	20,500
(YOY%)	(-22.0%)	(-2.9%)	(+23.6%)	(+3.7%)	(-43.2%)	(-68.1%)	(-47.3%)	(-17.5%)	(+5.7%)
Earnings before the amortization of goodwill and trademarks	8,494	18,464	25,830	31,438	6,192	10,245	18,211	28,400	32,400
Prescription Pharmaceutical operations (YOY%)	4,466	4,857	5,496	2,495	15	-721	-289	-3,000	-4,000
	(+178.1%)	(+104.0%)	(+15.9%)	(-39.8%)	(-99.7%)	(-114.8%)	(-105.3%)	(-220.2%)	(-260.3%)
Other*	-561	-1,087	-1,488	-1,925	-451	-959	-1,466	-2,000	-2,000
(YOY%)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Total	9,389	16,295	20,864	19,965	2,676	2,313	7,133	11,000	14,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

** Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2021(FY2020)**				March 2022(FY2021)**						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (New)	YOY	Full year E (Previous)
Japan*	27.0	60.6	92.4	123.0	28.9	62.8	96.3	+4.3%	129.4	+5.2%	131.3
Lipovitan series	10.4	24.4	35.9	45.8	11.8	26.2	38.4	+7.2%	49.0	+7.0%	49.0
Pabron series	3.5	9.1	15.6	21.1	3.5	9.4	15.0	-4.0%	21.6	+2.1%	22.0
RiUP series	3.5	7.6	11.7	14.9	3.5	7.0	11.1	-5.2%	14.9	-0.0%	15.3
Biofermin series	2.4	4.9	7.4	9.8	2.5	5.3	8.0	+8.1%	10.6	+8.1%	10.3
NARON series	0.8	1.6	2.2	3.0	0.9	2.0	2.6	+15.2%	3.4	+12.0%	3.5
GI treatment series	0.8	1.6	2.5	3.4	0.8	1.6	2.6	+2.2%	3.5	+2.8%	3.5
VICKS series	0.5	1.4	2.5	3.1	0.5	1.2	2.2	-13.3%	2.9	-5.1%	3.5
Livita series	0.8	1.5	2.4	3.2	0.8	1.5	2.3	-3.6%	3.2	-0.9%	3.2
Colac series	0.8	1.5	2.4	3.1	0.7	1.5	2.3	-2.9%	3.1	-1.8%	3.1
Overseas*	26.7	47.1	67.2	91.7	24.3	46.7	72.3	+7.7%	100.4	+9.5%	98.0
Asia	11.5	19.6	29.2	41.6	12.0	24.0	35.8	+22.5%	48.6	+16.8%	46.1
Europe and America	15.0	27.2	37.6	49.7	12.1	22.5	35.7	-5.1%	50.7	+2.1%	50.9
Others*	0.5	1.2	1.9	2.4	0.5	1.0	1.1	-42.2%	1.3	-45.4%	1.8

(Rounded to the nearest hundred-million)

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

** The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2021(FY2020)*				March 2022(FY2021)*						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (New)	YOY	Full year E (Previous)
Lipovitan series	10.4	24.4	35.9	45.8	11.8	26.2	38.4	+7.2%	49.0	0.1	49.0
Lipovitan D	6.9	15.9	23.0	28.7	7.3	16.4	23.8	+3.3%	30.0	0.0	29.9
Others	3.5	8.5	12.8	17.1	4.5	9.8	14.6	+14.0%	19.0	0.1	19.1

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2021(FY2020)*				March 2022(FY2021)*						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (New)	YOY	Full year E (Previous)
<i>Lusefi</i>	2.6	5.2	8.3	10.8	3.1	6.2	9.7	+16.6%	12.8	+18.5%	12.8
<i>Bonviva</i>	1.7	3.4	5.3	6.9	1.8	3.6	5.7	+8.6%	7.4	+7.4%	7.4
<i>LOQOA</i>	0.9	1.9	3.0	3.8	1.0	1.9	3.2	+6.1%	4.1	+7.7%	4.1
<i>Biofermin</i>	1.1	1.8	2.5	3.4	1.1	2.2	3.5	+38.9%	4.5	+32.4%	4.5
<i>Clarith</i>	0.5	1.0	1.8	2.2	0.5	1.0	1.8	+1.7%	2.1	-4.0%	2.1
<i>Palux</i>	0.6	1.2	1.9	2.4	0.6	1.1	1.7	-6.9%	2.1	-11.8%	2.1
<i>Geninax</i>	1.8	2.2	2.2	2.2	-	-	-	-100.0%	0.4	-81.8%	0.4

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated: Capital Expenditure

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Total capital expenditure	2,659	5,701	8,182	15,121	1,779	7,749	10,553	16,600	17,600
Taisho Pharmaceutical	1,081	3,258	5,170	7,793	1,316	4,097	6,049	10,270	10,350
Production department	358	652	904	1,379	269	656	893	1,180	1,210
Research department	37	764	1,013	1,519	8	1,589	2,852	5,510	5,540
Head Office and the others	684	1,841	3,252	4,894	1,039	1,851	2,303	3,580	3,600
Other subsidiaries	1,578	2,443	3,012	7,327	462	3,652	4,504	6,330	7,250

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Depreciation and amortization	3,673	7,206	10,925	14,700	3,508	7,347	10,958	14,500	14,000
Cost of sales	1,393	2,687	4,082	5,278	1,280	2,621	3,790	4,900	4,700
SGA expenses	2,280	4,519	6,843	9,421	2,228	4,725	7,168	9,600	9,300

Consolidated: R&D Expenses

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (New)	Full year E (Previous)
Total R&D expenses	4,209	9,429	14,354	20,251	4,629	9,673	14,291	20,600	21,600
Self-Medication operations	1,578	3,469	5,374	7,492	1,952	4,013	5,805	8,200	7,900
Prescription Pharmaceutical operations	2,630	5,960	8,980	12,758	2,677	5,660	8,485	12,400	13,700

Major Subsidiaries and Affiliates

(As of December 31, 2021)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	100.0**
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspha Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 S\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
UPSA Switzerland A.G.	Switzerland	,000 CHF 100	SMG	100.0
UPSA Italy S.r.l.	Italia	,000 EUR 10	SMG	100.0
UPSA Belgium S.A.	Belgium	,000 EUR 62	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

* Ownership: including the portion of indirect ownership

** Shares were exchanged to become a subsidiary fully owned by Taisho Pharmaceutical Holdings Co., Ltd. on July 30, 2021.

Prescription Pharmaceutical Operations:

New Drug Development - Taisho Pharmaceutical

As of February 1 , 2022

In Japan

Filed

Lusefi (Oral)

< Application	> Type2 diabetes
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi® Orally disintegrating film drug (drug form added)

TS-152 (Injection)

< Application	> Articular rheumatism against which existing therapies have insufficient efficacy
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)-α antibody
< Remarks	> Generic name: Ozoralizumab (Genetical Recombination)

Phase 3

TS-071(Oral)

< Application	> Type2 diabetes (Pediatric)
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi®

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Phase 1

TS-172 (Oral)

< Application	> Hyperphosphatemia
< Development	> In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of February 1 , 2022

Overseas

Phase 2

TS-161 (Oral)

< Target disease > Depression

< In-house/Licensed-in > In-house

Phase 1

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

TS-142 (Oral)

< Target disease > Insomnia

< In-house/Licensed-in > In-house

Launch of New Products

As of February 1, 2022

New Products Since FY2021 2Q Earnings Announcement (November 9, 2021)

Self-Medication Operations

Lipovitan Kids Jelly strawberry flavor

< Description > A refreshing beverage (jelly type) containing vitamins B₁, B₂, B₆ and calcium, which are essential nutrients for growing children. The lineup currently includes two flavors with the addition of the grape flavor (no fruit juice) launched in January 2021. The package design features familiar Pokémon characters such as Pikachu and Piplup.

< Launch > November 2021

AdryS Blooming Coffet

< Description > A special seasonal limited set containing *the exclusive Coffret lotion*, *Active Lotion Deep Moist White Floral Fragrance*, *Essence Glow Mask*, *Moisture Night Gel* with ample moisturizing ingredients, and Coffret's exclusive mirror and pouch (both of these items are not for sale).

< Launch > December 2021

AdryS Moisture Night Gel

< Description > Medicated moisturizing gel for people with very dry skin who are concerned about dryness all year round. The gel combines moisturizing and whitening* functions caring for your skin immediately after application as well as while sleeping. It contains six naturally-derived moisturizing ingredients, in addition to the two active medicating ingredients, heparinoid and placenta extract.

* Suppresses melanin production and prevents dark spots and freckles due to sunburn.

< Launch > December 2021

Lipovitan DXα

< Description > A vitamin supplement containing taurine, a vitamin B complex (B₁, B₂, B₆, and B₁₂), vitamin C and vitamin E. Small film-coated tablets, approximately 9 mm in diameter, which are easy to swallow so that you can easily make taking them a habit. This is recommended for people who want to alleviate everyday fatigue, people who easily feel tired due to aging, and people who feel cold easily.

< Launch > December 2021

Launch of New Products

As of February 1, 2022

New Products Since FY2021 2Q Earnings Announcement (November 9, 2021)

Self-Medication Operations

VICKS Medicated Spray

< Description > A refreshing lemon-flavored sterilizing and disinfecting spray for oral care that contains the bactericidal ingredient CPC (cetylpyridinium chloride hydrate). When sprayed, the agent spreads instantaneously to disinfect and sterilize the oral cavity, suppressing hoarseness and pain caused by throat inflammation. It can also be used to eliminate bad breath when wearing a mask.

< Launch > December 2021

Lipovitan D Featuring *Demon Slayer: Kimetsu no Yaiba*

< Description > *Lipovitan D* with its attractively designed packaging featuring Tanjiro Kamado, Nezuko and many other characters from anime. The 10-bottle box comes in 3 designs (1, 2 and 3) and the bottle comes in 15 designs.

< Launch > January 2022

Lipovitan Jelly Featuring *Demon Slayer: Kimetsu no Yaiba*

< Description > *Lipovitan Jelly* with attractively designed packaging featuring Tanjiro Kamado, Nezuko and many other characters from anime. A total of eight combinations are available: four package designs and two outer box designs.

< Launch > January 2022

Lipovitan D Valentine's Day limited bottle

< Description > Two bottle designs feature cute hearts to appeal to people of all ages. The 10-bottle boxes sold through Taisho Pharmaceutical Direct also include the same design, two different colored hearts on the front and back. The 2-bottle packs sold at supermarkets have a heartwarming design in which the bottles can be seen through the heart-shaped cut out of the package.

< Launch > January 2022

RAIZIN TROPICAL CRUSH

< Description > Drink with a flavor produced in limited quantity for the *RAIZIN* Triple-0* energy drink series containing enXtra, a plant-derived ingredient that replaces caffeine. It has a fruity flavor with a sweet and sour taste, like a mixture of a variety of tropical fruits in a refreshing atmosphere. The can is designed with the motif of a sunset on a tropical seashore, with a gradient blending into the ocean blue.

*Zero caffeine, zero calories, and zero sugar.

< Launch > January 2022

Launch of New Products

As of February 1, 2022

New Products Since FY2021 2Q Earnings Announcement (November 9, 2021)

Self-Medication Operations

HONZO DAISAIKOTO EXTRACT TABLETS—H

< Description > Oral Chinese herbal medicine effective for obesity and habitual constipation in people who have hard bowel movements, which contains 1,700 mg (12 tablets per day) of Daisaikoto extract made from 8 crude drugs.

< Launch > January 2022

Coppertone Secret Change UV

< Description > Sunscreen with a tone-up* function that brightens your skin color. It also has a UV cut function of SPF50⁺ and PA++++. You can choose from a total of five color variations, depending on your preferred skin impression and your mood on that day. You can also customize your look using different colors for different parts of the face, such as your cheeks or nose, or by coating with sunscreen of different colors.

*Due to makeup effect.

< Launch > February 2022

Coppertone Shiny Smooth Powder

< Description > Facial powder to be used on top of *Coppertone Secret Change UV* for finishing that adsorbs sebum and suppresses oiliness to keep the skin smooth.

< Launch > February 2022
